Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Total Debt (2018 - 2022)

Lipocine's Total Debt history spans 5 years, with the latest figure at $1.5 million for Q1 2022.

  • For Q1 2022, Total Debt fell 68.96% year-over-year to $1.5 million; the TTM value through Mar 2022 reached $1.5 million, down 68.96%, while the annual FY2021 figure was $2.3 million, 58.66% down from the prior year.
  • Total Debt reached $1.5 million in Q1 2022 per LPCN's latest filing, down from $2.3 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $10.3 million in Q4 2018 to a low of $1.5 million in Q1 2022.
  • Average Total Debt over 5 years is $6.7 million, with a median of $6.4 million recorded in 2020.
  • Peak YoY movement for Total Debt: decreased 5.68% in 2019, then tumbled 68.96% in 2022.
  • A 5-year view of Total Debt shows it stood at $10.3 million in 2018, then crashed by 30.33% to $7.1 million in 2019, then fell by 21.79% to $5.6 million in 2020, then plummeted by 58.66% to $2.3 million in 2021, then plummeted by 35.86% to $1.5 million in 2022.
  • Per Business Quant, the three most recent readings for LPCN's Total Debt are $1.5 million (Q1 2022), $2.3 million (Q4 2021), and $3.1 million (Q3 2021).